CORTIMENT (budesonide), corticosteroid for local use

GASTROENTEROLOGY - New medicinal product

Opinions on drugs - Posted on Mar 29 2017

Inclusion

CORTIMENT has Marketing Authorisation for inducing remission in mild to moderate forms of ulcerative colitis (UC) for which treatment with 5-ASA is not sufficient.
Its efficacy is modest, but it has fewer side effects than systemic corticosteroid therapy.
It has not been compared with an active treatment: 5-ASA or especially a systemic corticosteroid.

Substantial

no clinical added value

Therapeutic use

Évaluation des médicaments

All our publications

My account